The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs.
作者： Carlos Martin , Ann Williams , Rogelio Hernandez-Pando , Pere J Cardona , Eamonn Gormley
DOI: 10.1016/J.VACCINE.2006.03.017
关键词:
摘要: The Mycobacterium tuberculosis phoP mutant strain SO2 has previously been shown to have reduced multiplication in mouse macrophages and vivo using the intravenous-infection model. In this study we demonstrate that M. is highly attenuated when compared with parental MT103 also more than BCG severe combined immunodeficiency disease (SCID) mice. Complementation of wild-type gene restored virulence SCID mice, confirming phenotype due mutation. Balb/c mice subcutaneously vaccinated either or BCG, proportions CD4+ CD8+ populations measured spleen were significantly higher group. addition, proportion antigen-stimulated CD4+/CD8+ cells expressing IFN-γ was group protected against intra-venous challenge H37Rv at levels comparable as by bacterial counts lung spleens. Guinea pigs aerosol delivered different doses. A high dose guinea resulted superior protection vaccination, pig survival reduction severity lung.
uab.cat
elsevier.com
sci-hub.se 参考文章(39)
Stefan H. E. Kaufmann, Is the development of a new tuberculosis vaccine possible Nature Medicine. ,vol. 6, pp. 955- 960 ,(2000) , 10.1038/79631
Jeffery S. Cox, Bing Chen, Michael McNeil, William R. Jacobs, Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature. ,vol. 402, pp. 79- 83 ,(1999) , 10.1038/47042
Alexander S. Pym, Priscille Brodin, Roland Brosch, Michel Huerre, Stewart T. Cole, Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Molecular Microbiology. ,vol. 46, pp. 709- 717 ,(2002) , 10.1046/J.1365-2958.2002.03237.X
Esther Pérez, Sofía Samper, Yann Bordas, Christophe Guilhot, Brigitte Gicquel, Carlos Martín, An essential role for phoP in Mycobacterium tuberculosis virulence. Molecular Microbiology. ,vol. 41, pp. 179- 187 ,(2001) , 10.1046/J.1365-2958.2001.02500.X
Arun T. Kamath, Uli Fruth, Michael J. Brennan, Roland Dobbelaer, Peter Hubrechts, Mei Mei Ho, Ronald E. Mayner, Jelle Thole, K. Barry Walker, Margaret Liu, Paul-Henri Lambert, New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine. ,vol. 23, pp. 3753- 3761 ,(2005) , 10.1016/J.VACCINE.2005.03.001
D. Wilkinson, Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229) Transactions of The Royal Society of Tropical Medicine and Hygiene. ,vol. 92, pp. 238- 238 ,(1998) , 10.1016/S0035-9203(98)90766-0
Alexander S. Pym, Priscille Brodin, Laleh Majlessi, Roland Brosch, Caroline Demangel, Ann Williams, Karen E. Griffiths, Gilles Marchal, Claude Leclerc, Stewart T. Cole, Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Medicine. ,vol. 9, pp. 533- 539 ,(2003) , 10.1038/NM859
Ian M. Orme, Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine. ,vol. 24, pp. 2- 19 ,(2006) , 10.1016/J.VACCINE.2005.07.078
Helen McShane, Ansar A Pathan, Clare R Sander, Sheila M Keating, Sarah C Gilbert, Kris Huygen, Helen A Fletcher, Adrian V S Hill, Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine. ,vol. 10, pp. 1240- 1244 ,(2004) , 10.1038/NM1128
Douglas B. Young, Building a better tuberculosis vaccine. Nature Medicine. ,vol. 9, pp. 503- 504 ,(2003) , 10.1038/NM868